Status:

ACTIVE_NOT_RECRUITING

Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions:

Whole Brain Radiotherapy

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer

Detailed Description

This was a single-center, single-arm trail. Enrolled patients were pathologically diagnosed with small cell lung cancer and had completed at least 4 cycles of first-line chemotherapy. Patients with br...

Eligibility Criteria

Inclusion

  • Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria.
  • The expected survival time is more than 3 months.
  • Intracranial metastases ≤10.
  • Adequate organ and bone marrow function.

Exclusion

  • Patients who have used antiangiogenic drugs within the previous 1 month.
  • Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer).
  • Small cell lung cancer with hilar invasion or hemoptysis.
  • Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage.
  • An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment.
  • Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications.
  • Patients with life-threatening conditions of other severe and/or uncontrolled diseases.

Key Trial Info

Start Date :

August 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 30 2025

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06611657

Start Date

August 20 2021

End Date

July 30 2025

Last Update

October 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China, 100021